---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053598"
form_type: "8-K"
ticker: null
cik: "0001845337"
company_name: "Day One Biopharmaceuticals, Inc."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:24:20.552830+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Day One Biopharma Q1 net loss $62.4M, launches OJEMDA after April FDA approval

## Summary
- Q1 2024 net loss $62.4M vs $42.4M YoY; cash $317.9M expected to fund ops into 2026.
- OJEMDA (tovorafenib) received FDA accelerated approval in April for relapsed/refractory BRAF-altered pLGG; first prescriptions written.
- R&D expenses $40.2M (up from $27.8M) driven by compensation, PRV buyback, and clinical activities.
- Phase 3 FIREFLY-2 front-line pLGG trial enrolling with >90 sites activated globally.
- Rare pediatric disease priority review voucher received upon OJEMDA approval.

## SEC filing metadata
- accession: 0000950170-24-053598
- form_type: 8-K
- cik: 0001845337
- company_name: Day One Biopharmaceuticals, Inc.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1845337/000095017024053598/0000950170-24-053598-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1845337/000095017024053598/dawn-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053598
- JSON: https://secwatch.observer/filing/0000950170-24-053598.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053598.txt

## Key facts
- Earnings Releases
  Day One Biopharmaceuticals, Inc. reported the quarter ended March 31, 2024 results: net income $62.4 million.
  - Period: the quarter ended March 31, 2024
  - Net income: $62.4 million
  - Result: reported results
  source text: Day One Biopharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1845337/000095017024053598/0000950170-24-053598-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.